Skipping Informed Consent for In Vitro Diagnostic (IVD) Trials: Understanding the Exceptions

Understanding the exceptions in Informed consent is an essential aspect of ethical clinical research because it concerns full awareness of risks and benefits related to research, as well as procedures. There is a need for conditions in which informed consent can be legitimately waived in IVD trials; hence, knowledge of those exceptions is significant for researchers to remember in ensuring regulatory standards are followed and participant rights safeguarded.

1. Minimal Risk and Minimal Harm: Research is one of the significant conditions under which waiver of informed consent can occur if it involves minimal risk to participants. If the research presents no more than minimal risk of harm to subjects then it need not involve any procedures for which written consent is required outside of the research context. For instance, in IVD trials, this could apply to studies conducted with left-over de-identified specimens where the risk to the participant is negligible.
2. Public Health Emergencies: In emergency public health diagnosis, prevention, or treatment needs, the requirement to provide informed consent can be exempted. This is particularly relevant for infectious diseases where rapid diagnosis and treatment are important in disease control before its spread.
3. Practicability: Sometimes, gaining informed consent is impossible without severely compromising the integrity of the research especially when the research could not practicably be carried out without the waiver or alteration. This can occur in studies with vast numbers of samples or when contacting each of a large number of participants is not logistically possible, such as with retrospective studies using archived samples.
4. Use of Leftover Specimens: The FDA allows some IVD clinical trials to be conducted without the need for informed consent if the samples meet specific criteria: the IVD test does not require IDE submission; leftover specimens collected for routine clinical care and otherwise discarded are used; specimens are not individually identifiable; individuals caring for patients are different from those conducting the clinical trial; specimens are provided to investigators without identifiers that can uniquely identify the patient; and the clinical trial is overseen by an IRB following 21 CFR 56.
5. Regulatory and Institutional Review Board Approval: Any informed consent waiver should be reviewed and approved by an IRB or an EC. FDA guidelines state, “An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds that the research presents no more than minimal risk.” At all costs, the IRB must ensure that the waiver meets regulatory criteria for the protection of rights and welfare.
6. Quality Assurance and Improvement Activities: Some quality assurance and improvement activities—those aiming to improve the quality of care rather than contribute to generalized knowledge—may also be exempt from the need to obtain informed consent. Per 21 CFR 50.23, “The waiver or alteration will not adversely affect the rights and welfare of the subjects.” Generally, such activities are done to improve clinical practices and carry no additional risks than those involved in regular care.

While the informed consent process is a cardinal ethical condition in clinical research, there are conditions under which its demand can be waived during IVD trials. This should, however, be guided by general guidelines to achieve a balance between the need for scientific advancement and the protection of participant rights. The researcher has to tread carefully and ensure that if consent is to be waived, it is justified, ethically reasonable, and sanctioned by the correct regulator. These are the informed conditions that make it possible for researchers to design and conduct IVD trials in an ethically responsible and scientifically valid manner, with the ultimate effect of advancing medical knowledge and public health.

Cloudbyz eClinical is one of the fastest growing cloud based eClinical systems natively built on the Salesforce platform. Our solutions help customers of all sizes conduct clinical trials efficiently to bring life saving therapies faster to market and improve patient lives. Our eClinical platform comprises CTMS, EDC, eTMF, Safety & Pharmacovigilance and Patient Recruitment solutions.

To know more about the Cloudbyz Unified eClinical Platform contact info@cloudbyz.com